Il fluticasone nella terapia del bambino asmatico: Effetti a breve termine sulla crescita

Translated title of the contribution: Fluticasone in the therapy of asthmatic children: Short-term effects on growth

E. Bozzola, C. Meazza, F. Prodam, G. Bona, M. Bozzola

Research output: Contribution to journalArticle

Abstract

Aim. Inhaled corticosteroids (ICS), for years used in the therapy of low-moderate bronchial asthma, reduce the rate of asthmatic attack with improved pulmonary functioning and quality of life. Clinical trials have been addressed mainly to study the efficacy rather than the safety of drugs, so that the side effects of these drugs have not yet been accurately defined. Clinical experience shows that growth delay appears in the first months of therapy with ICS. The aim of the study was to evaluate the influence of the therapy with spacer-administered inhaled corticosteroid on short-term auxological development in prepubertal children. Methods. In a group of children with low asthma, height and weight have been evaluated before and after six months of inhaled therapy with dipropionate fluticasone at a dose of 100 μg per day. Results. Twenty-five patients (19 males and 6 females; age 5.5±1.6 years; range: 2.6-7.8 years) showed a regular growth during the six months of therapy (mean height 0.8 standard deviation score [SDS] before therapy and 0.8 SDS after therapy), while 21 (17 males and 4 females; age 10.0±1.5 years; range 8.0-12.7 years) showed an increment of growth rate (mean height from 0.5 SDS to 0.7 SDS, respectively). Conclusion. Spacer-administered low dose fluticasone does not negatively influence short-term growth rate, regardless of the age of the patients.

Original languageItalian
Pages (from-to)163-168
Number of pages6
JournalMinerva Pediatrica
Volume60
Issue number2
Publication statusPublished - Apr 2008

Fingerprint

Growth
Adrenal Cortex Hormones
Drug-Related Side Effects and Adverse Reactions
Therapeutics
Asthma
Fluticasone
Quality of Life
Clinical Trials
Safety
Weights and Measures
Lung

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Il fluticasone nella terapia del bambino asmatico : Effetti a breve termine sulla crescita. / Bozzola, E.; Meazza, C.; Prodam, F.; Bona, G.; Bozzola, M.

In: Minerva Pediatrica, Vol. 60, No. 2, 04.2008, p. 163-168.

Research output: Contribution to journalArticle

@article{6949e988f641405ba7cc34d96497a007,
title = "Il fluticasone nella terapia del bambino asmatico: Effetti a breve termine sulla crescita",
abstract = "Aim. Inhaled corticosteroids (ICS), for years used in the therapy of low-moderate bronchial asthma, reduce the rate of asthmatic attack with improved pulmonary functioning and quality of life. Clinical trials have been addressed mainly to study the efficacy rather than the safety of drugs, so that the side effects of these drugs have not yet been accurately defined. Clinical experience shows that growth delay appears in the first months of therapy with ICS. The aim of the study was to evaluate the influence of the therapy with spacer-administered inhaled corticosteroid on short-term auxological development in prepubertal children. Methods. In a group of children with low asthma, height and weight have been evaluated before and after six months of inhaled therapy with dipropionate fluticasone at a dose of 100 μg per day. Results. Twenty-five patients (19 males and 6 females; age 5.5±1.6 years; range: 2.6-7.8 years) showed a regular growth during the six months of therapy (mean height 0.8 standard deviation score [SDS] before therapy and 0.8 SDS after therapy), while 21 (17 males and 4 females; age 10.0±1.5 years; range 8.0-12.7 years) showed an increment of growth rate (mean height from 0.5 SDS to 0.7 SDS, respectively). Conclusion. Spacer-administered low dose fluticasone does not negatively influence short-term growth rate, regardless of the age of the patients.",
keywords = "Administration, inhalation, Asthma, Fluticasone, Growth",
author = "E. Bozzola and C. Meazza and F. Prodam and G. Bona and M. Bozzola",
year = "2008",
month = "4",
language = "Italian",
volume = "60",
pages = "163--168",
journal = "Minerva Pediatrica",
issn = "0026-4946",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "2",

}

TY - JOUR

T1 - Il fluticasone nella terapia del bambino asmatico

T2 - Effetti a breve termine sulla crescita

AU - Bozzola, E.

AU - Meazza, C.

AU - Prodam, F.

AU - Bona, G.

AU - Bozzola, M.

PY - 2008/4

Y1 - 2008/4

N2 - Aim. Inhaled corticosteroids (ICS), for years used in the therapy of low-moderate bronchial asthma, reduce the rate of asthmatic attack with improved pulmonary functioning and quality of life. Clinical trials have been addressed mainly to study the efficacy rather than the safety of drugs, so that the side effects of these drugs have not yet been accurately defined. Clinical experience shows that growth delay appears in the first months of therapy with ICS. The aim of the study was to evaluate the influence of the therapy with spacer-administered inhaled corticosteroid on short-term auxological development in prepubertal children. Methods. In a group of children with low asthma, height and weight have been evaluated before and after six months of inhaled therapy with dipropionate fluticasone at a dose of 100 μg per day. Results. Twenty-five patients (19 males and 6 females; age 5.5±1.6 years; range: 2.6-7.8 years) showed a regular growth during the six months of therapy (mean height 0.8 standard deviation score [SDS] before therapy and 0.8 SDS after therapy), while 21 (17 males and 4 females; age 10.0±1.5 years; range 8.0-12.7 years) showed an increment of growth rate (mean height from 0.5 SDS to 0.7 SDS, respectively). Conclusion. Spacer-administered low dose fluticasone does not negatively influence short-term growth rate, regardless of the age of the patients.

AB - Aim. Inhaled corticosteroids (ICS), for years used in the therapy of low-moderate bronchial asthma, reduce the rate of asthmatic attack with improved pulmonary functioning and quality of life. Clinical trials have been addressed mainly to study the efficacy rather than the safety of drugs, so that the side effects of these drugs have not yet been accurately defined. Clinical experience shows that growth delay appears in the first months of therapy with ICS. The aim of the study was to evaluate the influence of the therapy with spacer-administered inhaled corticosteroid on short-term auxological development in prepubertal children. Methods. In a group of children with low asthma, height and weight have been evaluated before and after six months of inhaled therapy with dipropionate fluticasone at a dose of 100 μg per day. Results. Twenty-five patients (19 males and 6 females; age 5.5±1.6 years; range: 2.6-7.8 years) showed a regular growth during the six months of therapy (mean height 0.8 standard deviation score [SDS] before therapy and 0.8 SDS after therapy), while 21 (17 males and 4 females; age 10.0±1.5 years; range 8.0-12.7 years) showed an increment of growth rate (mean height from 0.5 SDS to 0.7 SDS, respectively). Conclusion. Spacer-administered low dose fluticasone does not negatively influence short-term growth rate, regardless of the age of the patients.

KW - Administration, inhalation

KW - Asthma

KW - Fluticasone

KW - Growth

UR - http://www.scopus.com/inward/record.url?scp=45549098508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45549098508&partnerID=8YFLogxK

M3 - Articolo

C2 - 18449132

AN - SCOPUS:45549098508

VL - 60

SP - 163

EP - 168

JO - Minerva Pediatrica

JF - Minerva Pediatrica

SN - 0026-4946

IS - 2

ER -